Shunsuke Maehara

List of Publications by Year
in descending order

14	162	1163117 8	1125743 13
papers	citations	h-index	g-index

14	14	14	261
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Unique Antipsychotic Activities of the Selective Metabotropic Glutamate Receptor 1 Allosteric Antagonist 2-Cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 179-190.	2.5	47
2	Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia. Pharmacology Biochemistry and Behavior, 2008, 91, 140-149.	2.9	28
3	A Selective Phosphodiesterase 10A Inhibitor Reduces <scp>L</scp>â€Dopaâ€Induced Dyskinesias in Parkinsonian Monkeys. Movement Disorders, 2018, 33, 805-814.	3.9	19
4	Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDMâ€042 [(E)â€4â€(2â€(2â€(5,8â€dimethylâ€[1,2,4]triazolo[1,5â€•a) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 Td (] schizophrenia. Pharmacology Research and Perspectives, 2016, 4, e00241.	2.4	12
5	Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions. Brain Research Bulletin, 2011, 86, 146-151.	3.0	10
6	Antipsychotic effects of N-desmethylclozapine on sensorimotor gating function in rats â€" Possible involvement of activation of M1 muscarinic receptors. European Journal of Pharmacology, 2011, 667, 242-249.	3.5	9
7	Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in miceâ€"Possible involvement of muscarinic receptors. Brain Research, 2011, 1418, 111-119.	2.2	9
8	Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats. Pharmacological Reports, 2020, 72, 443-448.	3.3	8
9	Dopamine D 1 signaling involvement in the effects of the phosphodiesterase 10A inhibitor, PDM-042 on cognitive function and extrapyramidal side effect in rats. Behavioural Brain Research, 2017, 317, 204-209.	2.2	5
10	Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychoticâ€like effects without affecting cognitive enhancement and cataleptic effects in rats. Neuropsychopharmacology Reports, 2020, 40, 190-195.	2.3	5
11	Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDMâ€878. Neuropsychopharmacology Reports, 2020, 40, 182-189.	2.3	4
12	Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKMâ€833 [(R)â€Nâ€(pyridazinâ€3â€yl)â€4â€(7â€(trifluoromethyl)chromanâ€4â€yl)piperazineâ€1â€carboxamide] in rats: Potential for the treatment of inflammatory pain. Pharmacology Research and Perspectives, 2020, 8, e00569.	2.4	3
13	Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631. European Journal of Pharmacology, 2017, 811, 110-116.	3.5	2
14	Orexin 2 receptor is involved in orexin A-induced hyperlocomotion in rats. Pharmacological Reports, 2019, 71, 1147-1150.	3.3	1